Watson to Present at the 31st Annual J.P. Morgan Healthcare
Conference
PARSIPPANY, N.J., Dec. 21,
2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI),
a leading specialty pharmaceutical company, announced today that
Paul Bisaro, Watson's President and
Chief Executive Officer, will provide an overview and update of the
Company's business at the 31st Annual J.P. Morgan Healthcare
Conference on Wednesday, January 9,
2013 at 7:30 am PST
(10:30 am EST) at the Westin St.
Francis Hotel, San Francisco,
California. The presentation will be webcast live and can be
accessed on Watson Pharmaceuticals' Investor Relations Web site at
http://ir.watson.com. The webcast can also be accessed at the
following URL:
http://jpmorgan.metameetings.com/webcasts/healthcare13/directlink?ticker=WPI
An archived version will be available approximately one hour
after the live presentation ends and can be accessed at the same
locations for 90 days.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. (NYSE: WPI) is a global,
integrated specialty pharmaceutical company focused on developing,
manufacturing and distributing generic, brand and biosimilar
products. The Company has global and U.S. headquarters in
Parsippany, New Jersey, USA, and
international headquarters in Zug, Switzerland.
Watson is the world's third-largest generics prescription drug
manufacturer, with more than 750 products marketed globally through
operations in more than 60 countries. Watson's global branded
pharmaceutical business develops and markets products principally
in Urology and Women's Health, and is committed to developing
and marketing biosimilars products in Women's Health, Oncology and
other therapeutic categories. In addition, Watson is the
fourth-largest U.S. generic pharmaceutical product distributor
through its Anda, Inc. business, and also develops and out-licenses
generic pharmaceutical products outside of the U.S. through its
Medis third-party business. Watson has announced that it will
adopt a new global name – Actavis – effective in 2013.
For press release and other company information, visit Watson
Pharmaceuticals' Web site at http://www.watson.com.
CONTACTS:
|
Investors:
|
|
Lisa
DeFrancesco
|
|
(862)
261-7152
|
|
|
|
Media:
|
|
Charlie
Mayr
|
|
(862)
261-8030
|
(Logo:
http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)
SOURCE Watson Pharmaceuticals, Inc.